Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Recruiting Observational Study
Malignant Pleural Mesothelioma, Advanced
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Study type
Observational
Participants needed
15 (estimated)
Sponsor
Tianjin Medical University Second Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years old (including boundary values), regardless of gender. 2. Confirmed as late stage MPM patients who have failed immunotherapy. 3. The patient or their legal representative can understand and sign the informed consent form. 4. At least one lesion that can safely…
Contacts

Haitao Wang, Ph.D

+86-022-88326385

peterrock2000@126.com

CONTACT

Jinhuan Wang, Ph.D

+86-022-88326610

wjhhappy2008@163.com

CONTACT